{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:27:12Z","timestamp":1795177632963,"version":"4.10.3"},"reference-count":32,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal posttransplant complication of hematopoietic stem cell transplantation. We recently reported that survival for TA-TMA has been improved by early intervention with eculizumab, a complement C5 inhibitor, guided by pharmacokinetic\/pharmacodynamic (PK\/PD) model-informed precision dosing. However, patients with gastrointestinal bleeding showed poor survival, even when treated with more frequent doses. Our objective was to develop separate models in bleeding and nonbleeding patients with TA-TMA and to propose precision dosing algorithms. Eculizumab PK\/PD was analyzed in 19 bleeding and 38 nonbleeding patients (0.5-29.9 years of age). A complement activation biomarker (sC5b-9) and body weight were identified as significant determinants of eculizumab clearance regardless of bleeding. Eculizumab clearance after the first dose was higher in bleeding than in nonbleeding patients (83.8 vs 61.3 mL\/h per 70 kg; P = .07). The high clearance was maintained over treatment doses in bleeding patients, whereas nonbleeding patients showed a time-dependent decrease in clearance. sC5b-9 levels were highest before the first dose and decreased over time, regardless of bleeding complications. A Monte Carlo Simulation analysis showed that the current dosing protocols recommended for atypical hemolytic uremic syndrome had &amp;lt;15% probability of attaining the target concentration of &amp;gt;100 \u03bcg\/mL eculizumab in nonbleeding patients. We identified an intensified loading protocol to reach 80% target attainment. Our data clearly showed the need for individualized dosing for patients with significant bleeding and for ongoing dose adjustments to optimize outcomes. The developed models will be incorporated into a clinical decision guideline for precision dosing to improve outcomes in children and young adults with TA-TMA.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006523","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T17:05:33Z","timestamp":1641834333000},"page":"1454-1463","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT"],"prefix":"10.1182","volume":"6","author":[{"given":"Kana","family":"Mizuno","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4001-9203","authenticated-orcid":false,"given":"Christopher E.","family":"Dandoy","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;"},{"name":"Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Teusink-Cross","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella M.","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;"},{"name":"Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Vinks","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonata","family":"Jodele","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;"},{"name":"Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"issue":"4","key":"2022030216213925300_B1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood."},{"issue":"12","key":"2022030216213925300_B2","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood."},{"issue":"3","key":"2022030216213925300_B3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev."},{"issue":"3","key":"2022030216213925300_B4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/j.seminhematol.2018.04.003","article-title":"Complement in pathophysiology and treatment of transplant-associated thrombotic microangiopathies","volume":"55","author":"Jodele","year":"2018","journal-title":"Semin Hematol."},{"key":"2022030216213925300_B5","doi-asserted-by":"crossref","first-page":"564647","DOI":"10.3389\/fimmu.2020.564647","article-title":"Efficacy and safety of eculizumab in the treatment of transplant-associated thrombotic microangiopathy: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Immunol."},{"issue":"13","key":"2022030216213925300_B6","first-page":"1049","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood."},{"issue":"2","key":"2022030216213925300_B7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","article-title":"Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"2022030216213925300_B8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/cpt.659","article-title":"Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future","volume":"101","author":"Darwich","year":"2017","journal-title":"Clin Pharmacol Ther."},{"key":"2022030216213925300_B9","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.ejps.2017.05.037","article-title":"Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies","volume":"109S","author":"Mizuno","year":"2017","journal-title":"Eur J Pharm Sci."},{"issue":"1","key":"2022030216213925300_B10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/cpt.1679","article-title":"Development and implementation of electronic health record-integrated model-informed clinical decision support tools for the precision dosing of drugs","volume":"107","author":"Vinks","year":"2020","journal-title":"Clin Pharmacol Ther."},{"key":"2022030216213925300_B11","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1002\/jcph.1830","article-title":"Status toward the implementation of precision dosing in children","volume":"61","author":"Barrett","year":"2021","journal-title":"J Clin Pharmacol."},{"issue":"23","key":"2022030216213925300_B12","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med."},{"issue":"4","key":"2022030216213925300_B13","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2022030216213925300_B14","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"2","key":"2022030216213925300_B15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Programs Biomed."},{"issue":"4","key":"2022030216213925300_B16","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/psp.2013.14","article-title":"Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"7","key":"2022030216213925300_B17","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1038\/psp.2013.26","article-title":"Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance","volume":"2","author":"Byon","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"9","key":"2022030216213925300_B18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/archdischild-2013-303720","article-title":"Understanding dosing: children are small adults, neonates are immature children","volume":"98","author":"Anderson","year":"2013","journal-title":"Arch Dis Child."},{"issue":"2","key":"2022030216213925300_B19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12372","article-title":"Model-informed drug discovery and development: current industry good practice and regulatory expectations and future perspectives","volume":"8","author":"Marshall","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"10","key":"2022030216213925300_B20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s40262-017-0512-x","article-title":"Clinical trial simulations and pharmacometric analysis in pediatrics: application to inhaled loxapine in children and adolescents","volume":"56","author":"Dong","year":"2017","journal-title":"Clin Pharmacokinet."},{"issue":"6","key":"2022030216213925300_B21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/clpt.2009.199","article-title":"Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome","volume":"86","author":"Mouksassi","year":"2009","journal-title":"Clin Pharmacol Ther."},{"issue":"1","key":"2022030216213925300_B22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/11530560-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development","volume":"24","author":"Mould","year":"2010","journal-title":"BioDrugs."},{"issue":"9","key":"2022030216213925300_B23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"10","key":"2022030216213925300_B24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","article-title":"Population pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Dirks","year":"2010","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"2022030216213925300_B25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00467-010-1556-4","article-title":"aHUS caused by complement dysregulation: new therapies on the horizon","volume":"26","author":"Waters","year":"2011","journal-title":"Pediatr Nephrol."},{"issue":"10","key":"2022030216213925300_B26","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"issue":"17","key":"2022030216213925300_B27","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med."},{"issue":"11","key":"2022030216213925300_B28","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.5858\/arpa.2016-0599-RA","article-title":"A complete histologic approach to gastrointestinal biopsy from hematopoietic stem cell transplant patients with evidence of transplant-associated gastrointestinal thrombotic microangiopathy","volume":"141","author":"Warren","year":"2017","journal-title":"Arch Pathol Lab Med."},{"issue":"7","key":"2022030216213925300_B29","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn\u2019s disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther."},{"issue":"5","key":"2022030216213925300_B30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5414\/CPP48297","article-title":"Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis","volume":"48","author":"Fasanmade","year":"2010","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"2","key":"2022030216213925300_B31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40262-019-00804-x","article-title":"Population pharmacokinetics of an anti-PD-L1 antibody, durvalumab in patients with hematologic malignancies","volume":"59","author":"Ogasawara","year":"2020","journal-title":"Clin Pharmacokinet."},{"issue":"6","key":"2022030216213925300_B32","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cpt.2148","article-title":"Real-world infliximab pharmacokinetic study informs an electronic health record-embedded dashboard to guide precision dosing in children with Crohn\u2019s disease","volume":"109","author":"Xiong","year":"2021","journal-title":"Clin Pharmacol Ther."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/5\/1454\/1875979\/advancesadv2021006523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/5\/1454\/1875979\/advancesadv2021006523.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T11:22:24Z","timestamp":1646220144000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/5\/1454\/483419\/Eculizumab-precision-dosing-algorithm-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,3,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006523","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,2]]}}}